AstraZeneca to buy RSV vaccine maker Icosavax for up to $1.1 billion
Published
Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio. The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5…
#icosavax #rsv